The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, double-blind, placebo-controlled phase II study of AMG 386 in combination with cisplatin and capecitabine (CX) in patients (pts) with metastatic gastroesophageal adenocarcinoma.
Martin M. Eatock
Disclosure not yet available
Janos Szanto
Disclosure not yet available
Niall C. Tebbutt
Disclosure not yet available
Carolyn L. Bampton
Disclosure not yet available
Andrew H. Strickland
Disclosure not yet available
Manuel Valladares Ayerbes
Disclosure not yet available
Nuwan Nanayakkara
Disclosure not yet available
Yu-Nien Sun
Disclosure not yet available
Adeboye H. Adewoye
Disclosure not yet available
Gyorgy Bodoky
Disclosure not yet available